Method for Inducing Immune Response Against Middle East Respiratory Syndrome-Corona Virus Using Trimeric S1-CD40L Fusion Protein
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 16/201,409, filed Nov 27, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,529,411 | Polynucleotide Encoding Trimeric S1-CD40L Fusion Protein Immunogen Against Middle East Respiratory Syndrome-Corona Virus In force · Medium confidence UsedRemaining | King Abdulaziz University | In force | Medium confidence | ||
| US 11,660,334 | Method for Inducing Immune Response Against Middle East Respiratory Syndrome-Corona Virus Using Trimeric S1-CD40L Fusion Protein In force · High confidence | King Abdulaziz University | In force | High confidence | ||
| US 10,806,784 | Composition and Method for Treating Mers Lapsed Oct 20, 2024 on the fee record High confidence | King Abdulaziz University | Lapsed Oct 20, 2024 on the fee record | High confidence | ||
| US 10,849,972 | Trimeric S1-CD40L Fusion Protein Vaccine Against Middle East Respiratory Syndrome-Coronavirus Lapsed Dec 1, 2024 on the fee record High confidence | King Abdulaziz University | Lapsed Dec 1, 2024 on the fee record | High confidence | ||
| US 11,154,612 | MERS-CoV VACCINE WITH TRIMERIC S1-CD40L FUSION PROTEIN Lapsed Oct 26, 2025 on the fee record High confidence | King Abdulaziz University | Lapsed Oct 26, 2025 on the fee record | High confidence | ||
| US 11,219,685 | INTRANASAL MERS-CoV VACCINE Lapsed Jan 11, 2026 on the fee record High confidence | King Abdulaziz University | Lapsed Jan 11, 2026 on the fee record | High confidence | ||
| US 11,305,008 | Nucleic Acid Based Vaccine Against Middle East Respiratory Syndrome-Coronavirus Lapsed Apr 19, 2026 on the fee record High confidence | King Abdulaziz University | Lapsed Apr 19, 2026 on the fee record | High confidence | ||
| US 11,318,198 | MERS-CoV VACCINE COMPOSITION Lapsed May 3, 2026 on the fee record High confidence | King Abdulaziz University | Lapsed May 3, 2026 on the fee record | High confidence |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by King Abdulaziz University.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.